Avelumab

产品编号：MB2789

质量标准：>95%,蛋白原液

包装规格：1MG/5MG

产品形式：

基本信息

分子量	147KD
CAS NO	1537032-82-8
储存条件	-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light

简介：Avelumab 是一个人 IgG1 抗 PD-L1 单克隆抗体，具有潜在的抗体依赖性细胞介导的细胞毒性作用。

产品形式：蛋白原液 。每种装于冻存管中，单抗质量为标示数量 1MG 或者 5MG，体积根据其浓度不同略有不同。

质量标准：

Non-reduced CE-SDS:.....>90%;

SEC-HPLC:.....>95%;

Bacterial Endotoxins Test：.....<10EU/ml

Residual Proteins of HostCell: .....<100 ng/mg

Exogenous residual DNA: .....<100pg/mg

Residual Protein A: .....<100 ng/mg

Biological Activity:.....80% to 125% of standard

储存条件：-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.

使用建议：

meilunbio 提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量 1MG 或者 5MG，体积根据其浓度不同略有不同。

使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(meilunbio 货号 MA0028，去离子无菌水(细胞培养用水))或者 PBS（meilunbio 货号 MA0015PBS(1X),细胞培养级）。

不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。

稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，

举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml

对应 5MG 包装的蛋白原液体积为 5mg（质量）/50mg/ml(浓度)=0.1ML，

实验需求蛋白浓度为 10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入 0.4ML,即 400ul PBS 或者无菌去离子水即可。

若给药量为固定质量值，比如单次给药 0.5MG，对应蛋白原液给药体积为 10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。

稀释后的蛋白溶液，可于 2-8 度冷藏避光保存不超过 2 周，不建议长期储存。

避免反复冻融，每次冻融蛋白活性会降低约 5%左右。

生物活性（仅来自于公开文献，不保证其有效性）

描述	Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
靶点	PD-1/PD-L1
体外	Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold (P=0.01) in JHC7 cells relative to isotype control. When the cells are treated with IFN-γ, Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold; P=0.001), UM-Chor1 (7.34-fold; P<0.001), U-CH2 (2.6 fold; P=0.008), MUG-Chor1 (8.38-fold; P=0.0016). Avelumab effectively increases antibody-dependent cell-mediated cytotoxicity (ADCC) of both the non-cancer stem cell (CSC) and CSC subpopulations to the same degree. Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8+ T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs).
体内	Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant (P<0.01) reduction in the average tumor volume of the Avelumab-treated mice. Reduction in MB49 tumor growth in the mice treated with Avelumab is durable and leads to a significant (P<0.05) improvement in percent survival. Avelumab treatment of 10 mice with bladder tumors results in complete tumor regression in 8 mice, confirmed by histopathology. However, in mice depleted of either CD4 or CD8 cells, Avelumab treatment is much less effective in controlling bladder tumor burden with tumor breakthrough occurring in a higher frequency in mice depleted of CD4 T cells.

美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)

产品编号	品名.	Target
MB2806	aflibercept	VEGFR
MB2786	Alemtuzumab	CD52
MB2787	Alirocumab	PCSK9
MB2784	Adalimumab	TNF-α
MB2790	Atezolizumab	PDL-1
MB2791	Bevacizumab	VEGF
MB2792	Cetuximab	EGFR
MB2803	Daratumumab	CD38

MB2794	Denosumab	RANK Ligand
MB2023	Eculizumab	补体蛋白(C5)
MB2795	Etanercept	TNF
MB2797	Evolocumab	PCSK9
MB2773	Infliximab	TNF-α
MB2769	Ipilimumab	CTLA-4
MB2772	Matuzumab	EGFR
MB2766	Mepolizumab	IL-5
MB2767	Nivolumab	PD-1
MB2774	Obinutuzumab	CD20
MB2776	Ofatumumab	CD20
MB2777	Omalizumab	IgE
MB2781	Panitumumab	EGFR
MB2761	Pembrolizumab	PD-1
MB2762	Pertuzumab	HER2
MB2763	Ranibizumab	VEGFR
MB2938	Ramucirumab	VEGFR
MB2749	Rituximab	CD20
MB2757	Secukinumab	IL-17
MB2751	Tocilizumab/Atlizumab	IL-6 receptor
MB2753	Trastuzumab	ErbB2
MB2758	Ustekinumab	IL-12

用途及描述：仅供科研，严禁用于人体(For R&D Only)